Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;33(2):546-549.
doi: 10.1038/s41375-018-0272-0. Epub 2018 Sep 28.

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

Tobias W Klausen  1 , Henrik Gregersen  2 , Niels Abildgaard  3 , Niels Frost Andersen  4 , Ulf Christian Frølund  5 , Peter Gimsing  6 , Carsten Helleberg  1 , Annette J Vangsted  7
Affiliations

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

Tobias W Klausen et al. Leukemia. 2019 Feb.
No abstract available

PubMed Disclaimer

References

    1. Gimsing P, Holmström MO, Wirenfelt Klausen T, Frost Andersen N, Gregersen H, Pedersen RS, et al. The Danish national multiple myeloma registry. Clin Epidemiol. 2016;8:583–7. - DOI
    1. Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frolund UC, et al. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med. 2017;6:1807–16. - DOI
    1. Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin M-D, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood. 2016;127:1109–16. - DOI
    1. Abildgaard N, Vangsted A, Gregersen H, Andersen N, Pedersen R, Plesner T, et al. Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry. Clin Lymphoma, Myeloma Leuk. 2015;15:e189. - DOI
    1. Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of Phase III Randomized, Controlled Trials. J Clin Oncol. 2013;31:3279–87. - DOI

Publication types

LinkOut - more resources